Exact Sciences — Nov 3, 2025 release

2025 outlook The Company has updated its full-year 2025 revenue and adjusted EBITDA guidance: Prior guidance November 3 update Change at midpoint Y/Y growth rate Total revenue $3.130 - $3.170 billion $3.220 - $3.235 billion $77.5 million 17% Screening $2.440 - $2.470 billion $2.510 - $2.520 billion $60.0 million 20% Precision Oncology $690 - $700 million $710 - $715 million $17.5 million 9% Adjusted EBITDA $455 - $475 million $470 - $480 million $10.0 million 47% Third-quarter 2025 conference call & webcast Company management will host a conference call and webcast on Monday, November 3, 2025, at 5 p.m. ET to discuss third-quarter 2025 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties. Non-GAAP disclosure In addition to the Company's financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents the following non-GAAP measures: Core revenue — Core revenue is calculated to adjust for recent acquisitions and divestitures and foreign currency exchange rate fluctuatio